Literature DB >> 18039577

Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties.

Mary Mader1, Alfonso de Dios, Chuan Shih, Rosanne Bonjouklian, Tiechao Li, Wesley White, Beatriz López de Uralde, Concepción Sánchez-Martinez, Miriam del Prado, Carlos Jaramillo, Eugenio de Diego, Luisa M Martín Cabrejas, Carmen Dominguez, Carlos Montero, Timothy Shepherd, Robert Dally, John E Toth, Arindam Chatterjee, Sehila Pleite, Jaime Blanco-Urgoiti, Leticia Perez, Mario Barberis, María José Lorite, Enrique Jambrina, C Richard Nevill, Paul A Lee, Richard C Schultz, Jeffrey A Wolos, Li C Li, Robert M Campbell, Bryan D Anderson.   

Abstract

Herein we report investigations into the p38alpha MAP kinase activity of trisubstituted imidazoles that led to the identification of compounds possessing highly potent in vivo activity. The SAR of a novel series of imidazopyridines is demonstrated as well, resulting in compounds possessing cellular potency and enhanced in vivo activity in the rat collagen-induced arthritis model of chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18039577     DOI: 10.1016/j.bmcl.2007.10.106

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

Review 1.  Targeting innate immunity protein kinase signalling in inflammation.

Authors:  Matthias Gaestel; Alexey Kotlyarov; Michael Kracht
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

2.  Highly efficient water-mediated approach to access benzazoles: metal catalyst and base-free synthesis of 2-substituted benzimidazoles, benzoxazoles, and benzothiazoles.

Authors:  Manju Bala; Praveen Kumar Verma; Deepika Sharma; Neeraj Kumar; Bikram Singh
Journal:  Mol Divers       Date:  2015-03-11       Impact factor: 2.943

Review 3.  Strategies for Improving Photodynamic Therapy Through Pharmacological Modulation of the Immediate Early Stress Response.

Authors:  Daniel J de Klerk; Mark J de Keijzer; Lionel M Dias; Jordi Heemskerk; Lianne R de Haan; Tony G Kleijn; Leonardo P Franchi; Michal Heger
Journal:  Methods Mol Biol       Date:  2022

4.  1,3-Dibenzyl-6-bromo-1H-imidazo[4,5-b]pyridin-2(3H)-one.

Authors:  S Dahmani; Y Kandri Rodi; F Capet; El Mokhtar Essassi; Seik Weng Ng
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-03-06

5.  Ethyl 1-sec-butyl-2-(4-methoxy-phen-yl)-1H-benzimidazole-5-carboxyl-ate.

Authors:  Natarajan Arumugam; Aisyah Saad Abdul Rahim; Hasnah Osman; Madhukar Hemamalini; Hoong-Kun Fun
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-03-17

6.  Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier.

Authors:  Rong Zhao; Thomas J Raub; Geri A Sawada; Steven C Kasper; James A Bacon; Arlene S Bridges; Gary M Pollack
Journal:  Drug Metab Dispos       Date:  2009-03-09       Impact factor: 3.922

7.  1-Acetyl-6-bromo-1H-imidazo[4,5-b]pyridin-2(3H)-one.

Authors:  Siham Dahmani; Youssef Kandri Rodi; Santiago V Luis; El Mokhtar Essassi; Lahcen El Ammari
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-05-11

8.  Antituberculosis: synthesis and antimycobacterial activity of novel benzimidazole derivatives.

Authors:  Yeong Keng Yoon; Mohamed Ashraf Ali; Tan Soo Choon; Rusli Ismail; Ang Chee Wei; Raju Suresh Kumar; Hasnah Osman; Farzana Beevi
Journal:  Biomed Res Int       Date:  2013-12-05       Impact factor: 3.411

Review 9.  Kinase inhibitors as potential agents in the treatment of multiple myeloma.

Authors:  Hanley N Abramson
Journal:  Oncotarget       Date:  2016-12-06

10.  RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy.

Authors:  Adrian P Wiegmans; Mariska Miranda; Shu Wen Wen; Fares Al-Ejeh; Andreas Möller
Journal:  Oncotarget       Date:  2016-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.